Comparison of everolimus-eluting bioresorbable vascular scaffolds and metallic stents: three-year clinical outcomes from the ABSORB China randomised trial
EuroIntervention 2018;14:e554-e561 published online ahead of print October 2017 published online e-edition August 2018. DOI: 10.4244/EIJ-D-17-00796
Bo Xu1, MBBS; Yuejin Yang1, MD, PhD; Yaling Han2, MD, PhD; Yong Huo3, MD; Lefeng Wang4, MD; Xiangqian Qi5, MD; Jifu Li6, MD; Yundai Chen7, MD; Hai-Chien Kuo8, PhD; Shih-Wa Ying8, MS; Wai-Fung Cheong8, PhD; Yunlong Zhang8, MD; Xiaolu Su8, MS; Jeffery J. Popma9, MD; Runlin Gao1*, MD; Gregg W. Stone10, MD; on behalf of the ABSORB China Investigators
1. Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing, China; 2. General Hospital of Shenyang Military Region, Shenyang, China; 3. Peking University First Hospital, Beijing, China; 4. Beijing Chaoyan
Aims: Absorb bioresorbable vascular scaffolds (BVS) and XIENCE cobalt-chromium everolimus-eluting stents (CoCr-EES) had comparable angiographic and clinical outcomes up to one year in pat